Drug class
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor; targeted antineoplastic
Mechanism of action
Inhibits ALK kinase activity and downstream signalling in ALK-rearranged tumour cells; it also inhibits additional kinases including MET and ROS1 at pharmacologically relevant concentrations.
General use cases
- Treatment of adults with ALK-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have not previously received an ALK inhibitor, as detected by an FDA-approved test under the US ENSACOVE indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
